Dose-escalated hypofractionated intensity-modulated radiotherapy in high-risk carcinoma of the prostate: outcome and late toxicity.
AuthorsThomson, David J
Coote, Joanna H
Wylie, James P
Cowan, Richard A
Logue, John P
Livsey, Jacqueline E
AffiliationDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
MetadataShow full item record
AbstractBackground. The benefit of dose-escalated hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) in prostate cancer is not established. We report 5-year outcome and long-term toxicity data within a phase II clinical trial. Materials and Methods. 60 men with predominantly high-risk prostate cancer were treated. All patients received neoadjuvant hormone therapy, completing up to 6 months in total. Thirty patients were treated with 57 Gy in 19 fractions and 30 patients with 60 Gy in 20 fractions. Acute and 2-year toxicities were reported and patients followed longitudinally to assess 5 year outcomes and long-term toxicity. Toxicity was measured using RTOG criteria and LENT/SOMA questionnaire. Results. Median followup was 84 months. Five-year overall survival (OS) was 83% and biochemical progression-free survival (bPFS) was 50% for 57 Gy. Five-year OS was 75% and bPFS 58% for 60 Gy. At 7 years, toxicity by RTOG criteria was acceptable with no grade 3 or above toxicity. Compared with baseline, there was no significant change in urinary symptoms at 2 or 7 years. Bowel symptoms were stable between 2 and 7 years. All patients continued to have significant sexual dysfunction. Conclusion. In high-risk prostate cancer, dose-escalated hypofractionated radiotherapy using IMRT results in encouraging outcomes and acceptable late toxicity.
CitationDose-escalated hypofractionated intensity-modulated radiotherapy in high-risk carcinoma of the prostate: outcome and late toxicity. 2012, 2012:450246 Prostate Cancer
- Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity.
- Authors: Coote JH, Wylie JP, Cowan RA, Logue JP, Swindell R, Livsey JE
- Issue date: 2009 Jul 15
- Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
- Authors: Miralbell R, Mollà M, Rouzaud M, Hidalgo A, Toscas JI, Lozano J, Sanz S, Ares C, Jorcano S, Linero D, Escudé L
- Issue date: 2010 Sep 1
- Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study.
- Authors: Kitamura K, Shirato H, Shinohara N, Harabayashi T, Onimaru R, Fujita K, Shimizu S, Nonomura K, Koyanagi T, Miyasaka K
- Issue date: 2003 Jul-Aug
- Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
- Authors: Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A
- Issue date: 2005 Dec 1
- High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
- Authors: Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA
- Issue date: 2001 Sep